FDA Commissioner, Scott Gottlieb, MD, has created a new FDA working group of senior agency staff who will investigate ways to increase generic drug competition.
FDA Commissioner, Scott Gottlieb, MD, has created a new FDA working group of senior agency staff who will investigate ways to increase generic drug competition.
The agency has already taken steps to address what Gottlieb calls “gaming” of the regulatory system by some drug makers who seek to delay the approval of generic drugs. Thus far, the agency has begun work on a Drug Competition Action Plan, held a public meeting on the administration of the Hatch-Waxman Amendments, published a list of off-patent branded drugs that do not yet have approved generics, announced upcoming publication of 2 new documents designed to help generics companies navigate the Abbreviated New Drug Application process, and announced a new policy to expedite the review of generic drug applications.
The new initiative, Gottlieb said on Twitter, will expand upon the goals of the agency’s Action Plan:
The working group will also develop proposals to address ongoing difficulties in administering the Hatch-Waxman Amendments:
Yet the new initiative also seeks to move beyond those current efforts, and to identify new ideas and approaches that will improve access to generic drugs:
BioCentury reports that the working group’s membership includes Elizabeth Dickinson, JD, an FDA attorney in the Office of the Chief Counsel; Grail Sipes, JD, director of the Office of Regulatory Policy at the agency’s Center for Drug Evaluation and Research (CDER), and Maryll Toufanian, JD, deputy director of CDER’s Office of Generic Drug Policy.
The formation of the new working group follows Gottlieb’s recent congressional testimony, during which he highlighted barriers to competition in the pharmaceuticals marketplace. Among the barriers Gottlieb identified were restricted distribution systems and access to drugs for bioequivalence testing; single, shared systems for risk evaluation and mitigation strategies (REMS); citizen petitions, drugs not yet addressed under the 2006 Unapproved Drugs Initiative; and so-called “pay-for-delay” agreements, in which generics companies resolve patent disputes by agreeing to delay market entry in exchange for a sum of money.
Since his confirmation as FDA Commissioner in May, Gottlieb has made drug pricing a focus of the agency’s attention, and the formation of the working group suggests that these efforts to increase competition and drive down drug costs will only continue.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.